Lupin Announces FDA Approval For Risperidone
(RTTNews) - Lupin (LUPIN) has received approval from the FDA for its Abbreviated New Drug Application for Risperidone for extended-release injectable suspension, 25 mg per vial, 37.5 mg per vial, and 50 mg per vial, Single-Dose Vials. This is Lupin's first product using Nanomi B.V.'s technology and has a 180-day CGT exclusivity.
"Risperidone's U.S. FDA approval provides crucial validation of Nanomi's LAI technology platform and testifies to Lupin's ability to bring complex injectables to market," said Shahin Fesharaki, Chief Scientific Officer of Lupin.
For More Such Health News, visit rttnews.com.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.